159 related articles for article (PubMed ID: 22791365)
1. Patterns of bone density evaluation in a community population treated with aromatase inhibitors.
Ligibel JA; O'Malley AJ; Fisher M; Daniel GW; Winer EP; Keating NL
Breast Cancer Res Treat; 2012 Aug; 134(3):1305-13. PubMed ID: 22791365
[TBL] [Abstract][Full Text] [Related]
2. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
3. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
4. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
5. Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors.
Charlson J; Smith EC; Smallwood AJ; Laud PW; Neuner JM
J Natl Compr Canc Netw; 2016 Jul; 14(7):875-80. PubMed ID: 27407128
[TBL] [Abstract][Full Text] [Related]
6. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
7. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
[TBL] [Abstract][Full Text] [Related]
8. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
9. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
11. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
12. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
Becker T; Lipscombe L; Narod S; Simmons C; Anderson GM; Rochon PA
J Am Geriatr Soc; 2012 Sep; 60(9):1761-7. PubMed ID: 22985145
[TBL] [Abstract][Full Text] [Related]
14. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
16. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
17. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
18. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
Bailey S; Mhango G; Lin JJ
Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
[TBL] [Abstract][Full Text] [Related]
19. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
20. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]